Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs TransMedics Group Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.11 (market cap $44.49B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 16.2× TransMedics Group Inc's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and TransMedics Group Inc for 24 Days on average.
| JEPQ | TMDX | |
|---|---|---|
Market Cap | $44.49B | $2.74B |
Volume | 5,681,789 | 949,331 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $150.42 |
52-Week Low | $53.77 | $61.99 |
Typical Hold Time | 66 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.09, down 0.29% on the day, with a bullish technical signal driven by moving averages. The ETF maintains strong income generation through its covered-call strategy, with recent monthly dividends ranging from $0.57 to $0.70. Technical analysis shows support at $60-61 and resistance at $61-62, while oscillators remain neutral with RSI at 47.13.
JEPQ offers high monthly income potential with an estimated 11% yield, though its covered-call strategy limits upside appreciation. The ETF provides exposure to Nasdaq technology stocks with downside protection during volatility. Key risks include market correlation, income variability, and competition from other income ETFs. Institutional interest remains strong, with Envestnet recently increasing its position.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
